Anaspecmog The mog 35 55 peptide is a crucial tool in neuroscience research, particularly for understanding and modeling demyelinating diseasesMyelin Oligodendrocyte Glycoprotein (MOG) Associated Diseases - PubMed. This specific fragment of Myelin Oligodendrocyte Glycoprotein (MOG) is widely utilized to induce experimental autoimmune encephalomyelitis (EAE), a condition that closely mimics the pathological hallmarks of multiple sclerosis (MS) in animal models. By studying the effects of the MOG (35-55) peptide, researchers gain insights into the autoimmune processes that lead to neurological damage and disability.
Myelin Oligodendrocyte Glycoprotein (MOG) is a protein component of the myelin sheath in the central nervous system (CNS)作者：C Rich·2004·被引用次数：68—Moreover, Tg HLA-DR4-expressing mice injected with the myelin oligodendrocyte glycoprotein (MOG)-91–108peptidedevelopedpeptide-specific T .... The MOG 35-55 peptide represents a specific sequence within this larger protein, known to be a potent antigen. When introduced into an experimental subject, this peptide can trigger an immune response that targets the body's own myelin, leading to inflammation and demyelination.MOG (35-55), mouse, rat This process is instrumental in creating animal models that replicate key features of human neurological disorders.
The primary application of the mog 35 55 peptide is in the induction of Experimental Autoimmune Encephalomyelitis (EAE). This animal model is characterized by:
* Demyelination: The breakdown of the myelin sheath, which insulates nerve fibers, impairs nerve signal transmission.
* Neurological Symptoms: EAE often manifests as a relapsing-remitting neurological disease, with symptoms that can include paralysis and other motor deficits, mirroring the clinical presentation of multiple sclerosis.
* Autoimmune Response: The immune system mistakenly attacks myelin, driven by T cell responses against the MOG peptide.
Researchers use MOG (35-55) to study various aspects of these diseases, including the development of autoantibodies, the role of specific immune cells like T cells, and the efficacy of potential therapeutic interventionsMyelin oligodendrocyte glycoprotein (MOG) (35-55) is an antigenpeptideofMOG, a protein involved in demyelinating CNS disorders. ...MOG(35-55) in combination ....
Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous systemMOG 35–55 Peptide – Key Epitope in MS Research | p&e. The MOG (35-55) peptide has emerged as a key epitope in MS research because its induction of EAE produces a disease state with extensive plaque-like demyelination, a hallmark pathology of MS. Studies involving this peptide help to elucidate the mechanisms underlying MS pathogenesis, identify potential biomarkers, and test novel treatment strategies aimed at preventing or reversing demyelination and neuroinflammation. While MOG is a known target in some forms of MS, particularly in children, the MOG (35-55) fragment is a well-established tool for *modeling* the disease process in research settingsMyelin Oligodendrocyte Glycoprotein (MOG)35–55 ....
The mog 35 55 peptide is available in various forms, often specified by species (e.MOG (35-55) TFA (Myelin Oligodendrocyte Glycoprotein ...g.TheMOG peptide(35-55) has been described to induce autoimmune encephalomyelitis associated with Parkinson disease. It induces extensive plaque-like ..., human, mouse, rat) and purity levels, typically measured by HPLC.Thispeptideinduces severe chronic experimental autoimmune encephalomyelitis in transgenic mice. Researchers select specific versions of the peptide based on their experimental design and the animal models they are using. The peptide is commonly used in conjunction with adjuvants and myelin oligodendrocyte glycoprotein (MOG) emulsified forms to ensure a robust immune response. Beyond EAE induction, the peptide can also be employed in T cell assays and for generating anti-MOG antibodies in vitro and in vivo, further aiding in the study of autoimmune responses2014年4月15日—C57BL/6 mice are immunized with myelin oligodendrocyte glycoprotein (MOG)peptide 35-55(MOG35-55), resulting in an ascending flaccid paralysis caused by ....
In conclusion, the mog 35 55 peptide is an indispensable reagent for advancing our understanding of demyelinating diseases like multiple sclerosis. Its ability to reliably induce EAE provides a critical platform for investigating disease mechanisms and developing new therapies.2014年4月15日—C57BL/6 mice are immunized with myelin oligodendrocyte glycoprotein (MOG)peptide 35-55(MOG35-55), resulting in an ascending flaccid paralysis caused by ...
Join the newsletter to receive news, updates, new products and freebies in your inbox.